Seagen announces plans to expand pacific northwest biomanufacturing capacity to support growing portfolio of transformative cancer medicines

Bothell, wash.--(business wire)--seagen inc. (nasdaq: sgen) today announced plans to build a new facility in everett, washington, to expand the company's biomanufacturing capacity and enable the company greater control and flexibility over the production of its medicines to treat cancer. the 270,000-square-foot facility will be built north of the company's u.s. headquarters in bothell, washington. seagen expects to have the facility operational in 2024 and ultimately employ up to 200 highly ski
SGEN Ratings Summary
SGEN Quant Ranking